Chromium NEXT GEM Single Cell Library Prep Kits for NCATS ETB (Coronavirus/COVID-19)
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
General Information
- Contract Opportunity Type: Presolicitation (Original)
- Original Published Date: Jun 23, 2022 06:43 pm EDT
- Original Response Date: Jun 27, 2022 03:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date:
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- 334516 - Analytical Laboratory Instrument Manufacturing
- Place of Performance: CAUSA
Description
INTRODUCTION
PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT ACTION.
THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) intends to award a contract to 10x Genomics, Inc., 6230 Stoneridge Mall Road, Pleasanton, CA 94588-3260, titled: Chromium NEXT GEM Single Cell Library Prep Kits for NCATS ETB (Coronavirus/COVID-19). The rationale for this sole source is as follows:
NCATS has been using the 10x Genomics scRNAseq kits for BSL2 level viruses as well as SARS-CoV2 and continues to generate similar libraries for SARS-CoV2 infected tissues. It is important NCATS continues using these brand-name only kits from 10x Genomics for consistency of data and continuity of research. Additionally, only one source is reasonably available due to urgency. This is a Coronavirus/COVID-19 related action. The project these items will support is funded by an Intramural Targeted Anti-COVID-19 (ITAC) award to investigate single cell transcriptomic responses in respiratory virus infection on tissues to understand both SARS-CoV-2 variant pathogenesis and severe vs mild respiratory virus infections. These understandings are critical for the national response to Coronavirus/COVID-19 and related public health emergencies, and there is an urgent need for these items in order to advance these understandings as soon as possible.
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE
The intended procurement is classified under NAICS code 334516 with a small business size tandard of 1,000 employees.
REGULATORY AUTHORITY
The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) in effect through the Federal Acquisition Circular (FAC) at the time of award.
STATUTORY AUTHORITY
This acquisition is conducted as non-competitive under the authority of 41 U.S.C. 253(c) under provisions of the statutory authority of FAR Subpart 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.
DESCRIPTION OF REQUIREMENT
Background
The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. NCATS is improving health through smart science. The goal is to get more treatments to more patients more quickly. The Center develops, demonstrates and disseminates innovations that reduce, remove or bypass system-wide bottlenecks in the translational process. NCATS focuses on what is common across diseases and collaborates with other government agencies, including other NIH ICs; industry; academia; and patient support organizations.
Lung is one of the first organs where respiratory viral infection occurs, and severe diseases have been reported to occur in lung parenchyma. Thus, physiologically relevant in vitro lung models are highly demanded to help finding treatments and studying host responses to virus infections and drug treatments. NCATS has established protocols for barrier tissue models with vascularization using 3D bioprinting of required cellular components in a transwell format. The acquisition of the 10x Genomics brand single cell library kits (Chromium Next GEM Single Cell 3' Kit v3.1, 16 rxns) will provide the program an extensive opportunity to characterize single cell response in a 3D lung model to SARS-CoV2 and other high impact respiratory viruses.
Purpose and Objectives
To acquire brand-name only Chromium Next GEM cell library to characterize single cell response in a 3D lung model to SARS-CoV2 for NCATS ETB SARS-CoV-2 project.
Project Description
This requirement is for:
Product Brand-Name: Chromium Next GEM Single Cell 3’ Kit v3.1, 16 rxns
Manufacturer: 10x Genomics, Inc.
Part No. 1000268
Quantity: Two (2)
The salient physical, functional, or performance characteristics are as follows:
- Must be suitable for generating single cell RNA-Seq libraries from tissues for characterizing cell-based virus response and establishing tissues as a robust model.
- Primer must enable the production of barcoded, full-length cDNA from poly-adenylated mRNA.
- Must include primer sequences (Capture Sequence 1 and Capture Sequence 2) that enable capture and priming of Feature Barcoding technology compatible targets or analytes of interest.
Delivery Date
The anticipated delivery date is within 28-56 days after receipt of order (ARO).
CLOSING STATEMENT
This synopsis is not a request for competitive proposals; however, All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.
Responses to this solicitation must include clear and convincing evidence of the offeror’s technical capability of fulfilling the requirement. Responses that fail to include relevant technical capability information and all terms and conditions may be assessed as not capable of meeting the requirement.
The respondent must also provide their Unique Entity Identifier (UEI), organization name, address, point-of-contact, and size and type of business (e.g., 8(a), HubZone, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
All responses must be received by 03:00 PM Eastern Daylight Time, June 27, 2022, and reference number 75N95022Q00332.
All responses must be emailed to Mark McNally, Contracting Officer, at mark.mcnally@nih.gov.
All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.
Attachments/Links
Contact Information
Contracting Office Address
- c/o 3WFN MSC 6012 301 N Stonestreet Ave
- Bethesda , MD 20892
- USA
Primary Point of Contact
- Mark E McNally
- mark.mcnally@nih.gov
- Phone Number 3018275869
Secondary Point of Contact
History
- Jul 12, 2022 11:55 pm EDTPresolicitation (Original)